目的:评价激动剂方案中添加重组LH(rLH)的必要性。方法:计算机检索PubMed、Ovid、EMbase、Medline、Cochrane图书馆等中、外生物医学数据库。收集有关激动剂方案中是否添加rLH的随机对照试验。按Cochrane系统评价方法,评价所纳入研究的文献质量,并提取有效数据后采用RevMan5.1软件进行Meta分析。结果:纳入7个随机对照试验(RCT),共计1 741例患者,其中FSH+rLH组897例,FSH组844例。Meta分析结果显示:与FSH组比较,添加rLH对临床妊娠率(RR=0.99,95%CI=0.87~1.13,P=0.86)、活产率(RR=0.94,95%CI=0.76~1.16,P=0.57)、种植率(RR=1.00,95%CI=0.86~1.17,P=0.99)及流产率(RR=0.79,95%CI=0.52~1.22,P=0.29)无影响。但对于高龄患者,添加rLH降低了获卵数(WMD=-1.56,95%CI=-1.81~-1.32,P<0.001)及MⅡ卵数(WMD=-1.40,95%CI=-1.79~-1.01,P<0.001)。结论:与单独应用FSH相比,添加rLH对临床妊娠率、活产率、种植率及流产率无影响,但会减少高龄患者获卵数及MⅡ卵数。 Objective: To evaluate the need for addition of recombinant LH (rLH) to agonist regimens. Methods: The databases of Chinese and foreign biomedical databases such as PubMed, Ovid, EMbase, Medline and Cochrane Library were searched by computer. Collect randomized controlled trials about whether to add rLH in an agonist regimen. According to the Cochrane systematic review, the quality of the literature included in the study was evaluated, and validated data were extracted and analyzed using RevMan5.1 software. RESULTS: Seven randomized controlled trials (RCTs) were enrolled, totaling 1 741 patients, of whom 897 were FSH + rLH and 844 were FSH. The results of Meta analysis showed that the rate of clinical pregnancy (RR = 0.99, 95% CI = 0.87-1.13, P = 0.86), live birth rate (RR = 0.94, 95% CI 0.76-1.16, P = 0.57), implantation rate (RR = 1.00, 95% CI = 0.86-1.17, P = 0.99) and abortion rate (RR = 0.79, 95% CI = 0.52-1.22, P = 0.29). However, rLH decreased the number of oocytes (WMD = -1.56, 95% CI = -1.81 ~ -1.32, P <0.001) and MII oocytes (WMD = -1.40, 95% CI = -1.79 ~ 1.01, P <0.001). CONCLUSION: Compared with FSH alone, addition of rLH has no effect on clinical pregnancy rate, live birth rate, implantation rate and abortion rate, but will reduce the number of oocytes and M Ⅱ eggs in elderly patients.